If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 9 of 9
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Objective
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma Patients
Protocol No
UAB-21107-MASTER-2-MM
Categories
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Protocol No
GRACELL-GC012F-CD19-BCMA-001
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Objective
Study comparing new treatments for newly diagnosed AML with IDH2 gene change
Protocol No
SWOG-MM1OA-S03
Categories
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
Objective
Study of talquetamab in patients with R/R multiple myeloma
Protocol No
IIT-AKHTAR-CILTA-TALQ
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM
A Phase 1/2, Open-Label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
Objective
A Phase 1 2 Study of mRNA-2808 in Patients with Relapsed or Refractory Multiple Myeloma
Protocol No
MODERNA-MRNA-2808-P101
Categories
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
FIH study of ISB-2001 in R/R multiple myeloma subjects
Protocol No
ICHNOS-ISB-2001-101
Categories
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-Directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Len
Objective
A Phase 3 Study of BMS-986393 in Adult Patients with RR or RRMM
Protocol No
BMS-CA0881007